Posted by Michael Wonder on 20 Sep 2024
FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
20 September 2024 - Today, the FDA approved isatuximab-irfc (Sarclisa, Sanofi-Aventis) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplantation.
Efficacy was evaluated in IMROZ, an open-label, randomised, active-controlled Phase 3 trial in patients with newly diagnosed multiple myeloma who were not eligible for autologous stem cell transplantation.
